Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 3613 to 3618 of 3618 entries
Sorted by: Best Match Show Resources per page
Evaluation of Clinical Outcomes After Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units.

Open forum infectious diseases

Trachuk P, Hemmige V, Eisenberg R, Cowman K, Chen V, Weston G, Gendlina I, Ferguson N, Dicpinigaitis P, Berger J, Pirofski LA, Sarwar UN.
PMID: 34322562
Open Forum Infect Dis. 2021 Apr 15;8(7):ofab182. doi: 10.1093/ofid/ofab182. eCollection 2021 Jul.

BACKGROUND: Infection is a leading cause of admission to intensive care units (ICUs), with critically ill patients often receiving empiric broad-spectrum antibiotics. Nevertheless, a dedicated infectious diseases (ID) consultation and stewardship team is not routinely established. An ID-critical care...

Cite
Trachuk P, Hemmige V, Eisenberg R, et al. Evaluation of Clinical Outcomes After Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units. Open Forum Infect Dis. 2021;8(7):ofab182doi: 10.1093/ofid/ofab182.
Trachuk, P., Hemmige, V., Eisenberg, R., Cowman, K., Chen, V., Weston, G., Gendlina, I., Ferguson, N., Dicpinigaitis, P., Berger, J., Pirofski, L. A., & Sarwar, U. N. (2021). Evaluation of Clinical Outcomes After Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units. Open forum infectious diseases, 8(7), ofab182. https://doi.org/10.1093/ofid/ofab182
Trachuk, Polina, et al. "Evaluation of Clinical Outcomes After Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units." Open forum infectious diseases vol. 8,7 (2021): ofab182. doi: https://doi.org/10.1093/ofid/ofab182
Trachuk P, Hemmige V, Eisenberg R, Cowman K, Chen V, Weston G, Gendlina I, Ferguson N, Dicpinigaitis P, Berger J, Pirofski LA, Sarwar UN. Evaluation of Clinical Outcomes After Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units. Open Forum Infect Dis. 2021 Apr 15;8(7):ofab182. doi: 10.1093/ofid/ofab182. eCollection 2021 Jul. PMID: 34322562; PMCID: PMC8312519.
Copy Download .nbib Format: NLM
Pharmacokinetics of Vancomycin in Critically Ill Children: A Systematic Review.

European journal of drug metabolism and pharmacokinetics

Akunne OO, Mugabo P, Argent AC.
PMID: 34750740
Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):31-48. doi: 10.1007/s13318-021-00730-z. Epub 2021 Nov 08.

BACKGROUND AND OBJECTIVE: Vancomycin is often used in the ICU for the treatment of Gram-positive bacterial infection. In critically ill children, there are pathophysiologic changes that affect the pharmacokinetics of vancomycin. A systematic review of vancomycin pharmacokinetics and pharmacodynamics...

Cite
Akunne OO, Mugabo P, Argent AC. Pharmacokinetics of Vancomycin in Critically Ill Children: A Systematic Review. Eur J Drug Metab Pharmacokinet. 2021;47(1):31-48doi: 10.1007/s13318-021-00730-z.
Akunne, O. O., Mugabo, P., & Argent, A. C. (2022). Pharmacokinetics of Vancomycin in Critically Ill Children: A Systematic Review. European journal of drug metabolism and pharmacokinetics, 47(1), 31-48. https://doi.org/10.1007/s13318-021-00730-z
Akunne, Onyinye Onyeka, et al. "Pharmacokinetics of Vancomycin in Critically Ill Children: A Systematic Review." European journal of drug metabolism and pharmacokinetics vol. 47,1 (2022): 31-48. doi: https://doi.org/10.1007/s13318-021-00730-z
Akunne OO, Mugabo P, Argent AC. Pharmacokinetics of Vancomycin in Critically Ill Children: A Systematic Review. Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):31-48. doi: 10.1007/s13318-021-00730-z. Epub 2021 Nov 08. PMID: 34750740; PMCID: PMC8574943.
Copy Download .nbib Format: NLM
Molecular identification and in vitro evaluation of probiotic functional properties of some Egyptian lactic acid bacteria and yeasts.

Journal, genetic engineering & biotechnology

Ahmed AI, El Moghazy GM, Elsayed TR, Goda HAL, Khalafalla GM.
PMID: 34351550
J Genet Eng Biotechnol. 2021 Aug 05;19(1):114. doi: 10.1186/s43141-021-00212-4.

BACKGROUND: The health-promoting effects along with global economic importance of consuming food products supplemented with probiotic microorganisms encouraged the researchers to discover new probiotics.RESULTS: Fourteen lactic acid bacterial isolates were identified as Enterococcus mediterraneensis, Lactobacillus fermentum, and Streptococcus lutetiensis...

Cite
Ahmed AI, El Moghazy GM, Elsayed TR, et al. Molecular identification and in vitro evaluation of probiotic functional properties of some Egyptian lactic acid bacteria and yeasts. J Genet Eng Biotechnol. 2021;19(1):114doi: 10.1186/s43141-021-00212-4.
Ahmed, A. I., El Moghazy, G. M., Elsayed, T. R., Goda, H. A. L., & Khalafalla, G. M. (2021). Molecular identification and in vitro evaluation of probiotic functional properties of some Egyptian lactic acid bacteria and yeasts. Journal, genetic engineering & biotechnology, 19(1), 114. https://doi.org/10.1186/s43141-021-00212-4
Ahmed, Al-Shimaa Ibrahim, et al. "Molecular identification and in vitro evaluation of probiotic functional properties of some Egyptian lactic acid bacteria and yeasts." Journal, genetic engineering & biotechnology vol. 19,1 (2021): 114. doi: https://doi.org/10.1186/s43141-021-00212-4
Ahmed AI, El Moghazy GM, Elsayed TR, Goda HAL, Khalafalla GM. Molecular identification and in vitro evaluation of probiotic functional properties of some Egyptian lactic acid bacteria and yeasts. J Genet Eng Biotechnol. 2021 Aug 05;19(1):114. doi: 10.1186/s43141-021-00212-4. PMID: 34351550; PMCID: PMC8342691.
Copy Download .nbib Format: NLM
Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.

Infectious diseases and therapy

Jiang Y, Sarpong EM, Sears P, Obi EN.
PMID: 34292496
Infect Dis Ther. 2021 Jul 22; doi: 10.1007/s40121-021-00480-0. Epub 2021 Jul 22.

INTRODUCTION: Fidaxomicin is as effective as vancomycin in treating Clostridioides difficile infection (CDI) but more effective at preventing recurrence. However, because fidaxomicin is more costly than vancomycin, its overall value in managing CDI is not well understood. This study...

Cite
Jiang Y, Sarpong EM, Sears P, et al. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States. Infect Dis Ther. 2021;doi: 10.1007/s40121-021-00480-0.
Jiang, Y., Sarpong, E. M., Sears, P., & Obi, E. N. (2021). Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States. Infectious diseases and therapy, . https://doi.org/10.1007/s40121-021-00480-0
Jiang, Yiling, et al. "Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States." Infectious diseases and therapy vol. (2021). doi: https://doi.org/10.1007/s40121-021-00480-0
Jiang Y, Sarpong EM, Sears P, Obi EN. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States. Infect Dis Ther. 2021 Jul 22; doi: 10.1007/s40121-021-00480-0. Epub 2021 Jul 22. PMID: 34292496.
Copy Download .nbib Format: NLM
Isolation and Characterization of a Phage to Control Vancomycin Resistant .

Open life sciences

Raza T, Andleeb S, Ullah SR, Jamal M, Mehmood K, Ali M.
PMID: 33817126
Open Life Sci. 2018 Dec 31;13:553-560. doi: 10.1515/biol-2018-0066. eCollection 2018 Jan.

No abstract available.

Cite
Raza T, Andleeb S, Ullah SR, et al. Isolation and Characterization of a Phage to Control Vancomycin Resistant . Open Life Sci. 2018;13:553-560doi: 10.1515/biol-2018-0066.
Raza, T., Andleeb, S., Ullah, S. R., Jamal, M., Mehmood, K., & Ali, M. (2018). Isolation and Characterization of a Phage to Control Vancomycin Resistant . Open life sciences, 13553-560. https://doi.org/10.1515/biol-2018-0066
Raza, Taskeen, et al. "Isolation and Characterization of a Phage to Control Vancomycin Resistant ." Open life sciences vol. 13 (2018): 553-560. doi: https://doi.org/10.1515/biol-2018-0066
Raza T, Andleeb S, Ullah SR, Jamal M, Mehmood K, Ali M. Isolation and Characterization of a Phage to Control Vancomycin Resistant . Open Life Sci. 2018 Dec 31;13:553-560. doi: 10.1515/biol-2018-0066. eCollection 2018 Jan. PMID: 33817126; PMCID: PMC7874677.
Copy Download .nbib Format: NLM
Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from two German hospitals.

GMS hygiene and infection control

Nürnberger L, Schmidt D, Szumlanski T, Kirchhoff L, Ross B, Steinmann J, Rath PM.
PMID: 33796441
GMS Hyg Infect Control. 2021 Mar 17;16:Doc13. doi: 10.3205/dgkh000384. eCollection 2021.

No abstract available.

Cite
Nürnberger L, Schmidt D, Szumlanski T, et al. Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from two German hospitals. GMS Hyg Infect Control. 2021;16:Doc13doi: 10.3205/dgkh000384.
Nürnberger, L., Schmidt, D., Szumlanski, T., Kirchhoff, L., Ross, B., Steinmann, J., & Rath, P. M. (2021). Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from two German hospitals. GMS hygiene and infection control, 16Doc13. https://doi.org/10.3205/dgkh000384
Nürnberger, Laura, et al. "Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from two German hospitals." GMS hygiene and infection control vol. 16 (2021): Doc13. doi: https://doi.org/10.3205/dgkh000384
Nürnberger L, Schmidt D, Szumlanski T, Kirchhoff L, Ross B, Steinmann J, Rath PM. Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from two German hospitals. GMS Hyg Infect Control. 2021 Mar 17;16:Doc13. doi: 10.3205/dgkh000384. eCollection 2021. PMID: 33796441; PMCID: PMC7983015.
Copy Download .nbib Format: NLM
Showing 3613 to 3618 of 3618 entries